Format

Send to

Choose Destination
Eur J Cancer. 2018 Mar;92:20-32. doi: 10.1016/j.ejca.2017.12.023. Epub 2018 Feb 3.

Determinants and prognostic value of quality of life in patients with pancreatic ductal adenocarcinoma.

Author information

1
Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
2
Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
3
Department of Gastroenterology Hepatology & Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
4
Department of Oncology, Department of Medicine, Baylor College of Medicine Dan L Duncan Comprehensive Cancer Center, Houston, TX, USA.
5
Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Medical Institutions, Baltimore, MD, USA; Department of Oncology, The Sol Goldman Pancreatic Cancer Research Center, The Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins Medical Institutions, Baltimore, MD, USA.
6
Department of Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
7
Department of Medicine, University of California San Diego Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.
8
Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: xwu@mdanderson.org.

Abstract

BACKGROUND:

Quality of life (QOL) is impaired in pancreatic cancer patients. Our aim was to investigate the determinants and prognostic value of QOL after diagnosis in a hospital-based cohort of racially/ethnically diverse patients with pancreatic ductal adenocarcinoma (PDAC).

PATIENTS AND METHODS:

QOL was prospectively assessed using the Short Form-12 in 2478 PDAC patients. The Physical Component Summary (PCS) and Mental Component Summary (MCS) were categorised into tertiles based on their distribution. Ordered logistic regression was adopted to compare the risk of having lower PCS and MCS by patient sociodemographic and clinical characteristics. The association of PCS and MCS with mortality was assessed by Cox regression.

RESULTS:

Compared with non-Hispanic whites, Hispanics were at significantly higher risk of having lower PCS (odds ratio [95% CI], 1.69 [1.26-2.26]; P < 0.001) and lower MCS (1.66 [1.24-2.23]; P < 0.001). Patients diagnosed with stage III (1.80 [1.10-2.94]; P = 0.02) and stage IV (2.32 [1.50-3.59]; P < 0.001) PDAC were more likely to have lower PCS than stage I patients. Other determinants of QOL included sex, age, drinking, smoking, education level, comorbidities and time since diagnosis. The low tertile of PCS (hazard ratio [95% CI], 1.94 [1.72-2.18]; P < 0.001) and MCS (1.42 [1.26-1.59]; P < 0.001) were each related to poor prognosis. Similar results were found for non-Hispanic whites as compared with African-Americans/Hispanics/others.

CONCLUSION:

QOL after diagnosis is a significant prognostic indicator for patients with PDAC. Multiple factors determine QOL, suggesting possible means of intervention to improve QOL and outcomes of PDAC patients.

KEYWORDS:

Overall survival; Pancreatic ductal adenocarcinoma; Prognostic indicator; Quality of life; Short Form-12

PMID:
29413686
DOI:
10.1016/j.ejca.2017.12.023
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center